Company Description
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.
The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.
The company’s Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.
The company distributes its products through independent distributors and directly under the ESAB and DJO brands.
Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
| Country | United States |
| Founded | 1995 |
| IPO Date | May 8, 2008 |
| Industry | Specialty Industrial Machinery |
| Sector | Industrials |
| Employees | 6,550 |
| CEO | Matthew Trerotola |
Contact Details
Address: 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States | |
| Phone | 302 252 9160 |
| Website | enovis.com |
Stock Details
| Ticker Symbol | ENOV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001420800 |
| CUSIP Number | 194014502 |
| ISIN Number | US1940145022 |
| Employer ID | 54-1887631 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Matthew L. Trerotola | Chief Executive Officer and Chairman |
| Phillip Benjamin Berry | Senior Vice President and Chief Financial Officer |
| Patricia A. Lang | Senior Vice President and Chief Human Resources Officer |
| Daniel A. Pryor | Executive Vice President of Strategy and Business Development |
| Brady R. Shirley | Executive Advisor and Director |
| John Kleckner | Vice President, Controller and Chief Accounting Officer |
| Katie Sweet | Vice President of Corporate Communication |
| Tim Czartoski | President of U.S. Surgical and Global Product and Enabling Technologies |
| Terry Ross | Group President Prevention and Recovery |
| Brian P. Hanigan | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SCHEDULE 13G | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Aug 7, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 424B7 | Filing |
| Jun 28, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |